Reach further, in an Open Access Journal Endocrinology, Diabetes & Metabolism Case Reports

ISSN 1470-3947 (print)
ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology

Published by BioScientifica
Endocrine Abstracts (2010) 22 P391 

Anti-tumor activity of the tumor-vascular-disrupting agent ASA404 (vadimezan) in endocrine tumor models

Constanze Hantel1, Roman Franzev1, Alexandra Ozimek2, Thomas Mussack2 & Felix Beuschlein1

Author affiliations

Vascular disrupting agents (VDAs) differ from angiogenesis inhibitors by attacking established tumor blood vessels rather than preventing growth of new ones. We investigated effects of the tumor-VDA ASA404 against neuroendocrine tumors of the gastroenteropancreatic system (GEP-NETs) and adrenocortical carcinoma (ACC) 24 h after treatment of BON and NCIh295 tumor bearing mice with ASA404 (A), paclitaxel (P) or the combined administration (A+P). A significant decrease in cell proliferation (Ki 67 index, %) was detectable for BON tumors after all treatments (A: 51.6±0.7, P: 55.2±0.8 and A+P: 47.9±0.6; each P<0.0001 versus controls 60.2±0.8), for NCIh295 tumors only after P treatment (A: 46.6±1.5, P=0.87; P: 43.4±1.4, P<0.05 and A+P: 45.8±0.9, P=0.4; versus controls 46.88±1). BON tumors treated with A or A+P exhibited extensive necrotic areas not apparent in the control or P groups. TUNEL and CD31 staining showed that A or A+P treatments resulted furthermore in a significant increase of apoptotic cells (%) in BON tumor (A: 28.8±2.7, A+P: 34.3±3.6; each P<0.0001 versus controls 9.2±1.3 and P: 10.1±1.5) and a significant loss of microvessels compared with controls and P treatment (A: 7.3±0.8, P=0.0003 and A+P: 5.42±0.4, P<0.0001 versus controls 11.5±0.64 and versus P: 12.6±1.1). Interestingly, no significant effects on tumor morphology, apoptosis or microvessel density were detectable in NCIh295 tumors. To evaluate the mechanisms which cause these differences we initiated further in vitro analyses. As TNFα-signaling is assumed to mediate parts of ASA 404 induced effects we investigated induction of apoptosis and detected a fourfold higher rate of apoptosis in BON cells after TNFα treatment compared with NCIh295 cells (basal: 100%±2; BON: 823.1%±34.5 versus NCIh295: 244.2%±12.4; P=0.007). Thus, while ASA404 (vadimezan) treatment holds promise in the treatment of GEP-NETs, the utilized tumor models might help to delineate molecular mechanisms involved in VDA induced anti-tumor activity.

This Issue/Conference

Article tools

My recent searches